Evolus, Inc. EOLS R2K
Healthcare · Drug Manufacturers - Specialty & Generic · United States
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
READ MORE ›$6.56
-28.62% 1Y
Market & Price
Market Cap
$432.01M
Current Price
$6.56
High / Low (52W)
$10.24 / $3.94
Beta
1.29
Valuation
Stock P/E
-
Industry PE
23.65
Forward P/E
24.60
PEG Ratio
-
Book Value
$-0.44
Price to Book
-15.01
P/S
1.43
EV/EBITDA
-23.63
Dividend Yield
-
Profitability & Returns
ROCE
-20.77%
ROE
-
ROA
-9.06%
Profit Margin
-14.39%
Op Margin
-9.38%
EPS (Latest Qtr)
$-0.16
EPS (TTM)
$-0.66
Balance Sheet & Liquidity
Debt/Equity
-
Quick Ratio
1.50
Current Ratio
2.04
Debt
$164.90M
Total Assets
$225.87M
Current Assets
$142.92M
Working Capital
$67.61M
Ownership
Promoter Holding
14.68%
Chg in Prom Hold
-
FII / Inst Holding
70.05%
Chg in FII Hold
-
Financial Snapshot
Enterprise Value
$547.12M
Total Revenue (TTM)
$301.79M
EBITDA
$-23.15M
Free Cash Flow
$-23.23M
Operating Cash Flow
$-36.59M
Shares Outstanding
65.85M
Gross Margin
66.05%
Payout Ratio
0.00%
Growth (CAGR)
Revenue 5Y
25.98%
Profit 5Y
10.20%
Revenue (YoY)
6.70%
Earnings (YoY)
-
PROS
- Compounding revenue at 26.0% over 5 years.
- Profit CAGR of 10.2% over 5 years.
CONS
- Trading 35.9% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | EOLS Evolus, Inc. R2K | 6.56 | - | $432.01M | - | -20.77% | - | 25.98% | 10.20% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Ad space
Quarterly Results
Figures in USD.
| Metric | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 68.52M | 69.39M | 68.97M | 90.30M | 73.14M |
| Cost of Revenue | 21.87M | 24.07M | 23.13M | 31.01M | 24.24M |
| Gross Profit | 46.66M | 45.32M | 45.84M | 59.29M | 48.90M |
| Operating Expenses | 59.68M | 59.44M | 56.01M | 59.58M | 55.76M |
| Operating Income | -13.02M | -14.12M | -10.16M | -291.00K | -6.86M |
| EBITDA | -12.58M | -7.83M | -9.20M | 7.08M | -3.75M |
| Interest Expense | 4.42M | 7.21M | 4.09M | 3.98M | 3.98M |
| Pretax Income | -18.82M | -17.09M | -15.57M | 515.00K | -10.42M |
| Tax Provision | 72.00K | 53.00K | 167.00K | 385.00K | 256.00K |
| Net Income | -18.89M | -17.14M | -15.74M | 130.00K | -10.67M |
| Diluted EPS | -0.30 | -0.27 | -0.24 | 0.00 | -0.16 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 148.62M | 202.09M | 266.27M | 297.18M |
| Cost of Revenue | - | 58.84M | 64.51M | 83.97M | 100.07M |
| Gross Profit | - | 89.77M | 137.57M | 182.30M | 197.11M |
| Operating Expenses | - | 149.35M | 182.55M | 209.54M | 234.71M |
| Operating Income | - | -59.58M | -44.98M | -27.23M | -37.60M |
| EBITDA | - | -60.72M | -41.81M | -25.00M | -22.53M |
| Interest Expense | - | 9.10M | 13.83M | 18.73M | 19.69M |
| Pretax Income | - | -74.32M | -61.51M | -49.76M | -50.96M |
| Tax Provision | - | 95.00K | 176.00K | 664.00K | 677.00K |
| Net Income | - | -74.41M | -61.69M | -50.42M | -51.64M |
| Diluted EPS | - | -1.33 | -1.08 | -0.81 | -0.80 |
Compounded Sales Growth
| 5 Years: | 25.98% |
| 1 Year: | 6.70% |
Compounded Profit Growth
| 5 Years: | 10.20% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -28.62% |
| 6 Months: | -6.02% |
| 3 Months: | +52.56% |
| 1 Month: | +26.64% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 177.98M | 189.00M | 232.57M | 225.87M |
| Current Assets | - | 100.80M | 112.42M | 151.34M | 142.92M |
| Cash & Equivalents | - | 53.92M | 62.84M | 86.95M | 53.83M |
| Inventory | - | 18.85M | 11.00M | 12.16M | 26.96M |
| Receivables | - | 22.45M | 30.53M | 47.68M | 54.70M |
| Total Liabilities | - | 159.48M | 209.69M | 227.05M | 248.97M |
| Current Liabilities | - | 46.51M | 48.29M | 62.96M | 75.31M |
| Long Term Debt | - | 71.88M | 120.36M | 121.51M | 146.10M |
| Total Debt | - | 74.42M | 126.55M | 129.98M | 155.00M |
| Total Equity | - | 18.50M | -20.69M | 5.52M | -23.11M |
| Shares Outstanding | - | 56.26M | 57.82M | 63.50M | 65.01M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -84.91M | -34.01M | -18.00M | -42.27M |
| Investing Cash Flow | - | -2.94M | -1.63M | -4.82M | -8.45M |
| Financing Cash Flow | - | -4.15M | 44.64M | 47.41M | 17.34M |
| Capital Expenditure | - | -2.94M | -1.63M | -4.82M | -8.45M |
| Free Cash Flow | - | -87.85M | -35.63M | -22.82M | -50.72M |
| Net Change in Cash | - | -92.00M | 9.01M | 24.59M | -33.38M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 60.4% | 68.1% | 68.5% | 66.3% |
| Operating Margin % | - | -40.1% | -22.3% | -10.2% | -12.7% |
| Net Margin % | - | -50.1% | -30.5% | -18.9% | -17.4% |
| ROE % | - | -402.2% | 298.2% | -913.1% | 223.5% |
| ROCE % | - | -45.3% | -32.0% | -16.1% | -25.0% |
Shareholding Pattern
Insiders
14.68%
Institutions
70.05%
Public Float
82.10%
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Nantahala Capital Management, LLC | 9.68% | 6.38M | $41.83M |
| 2 | Blackrock Inc. | 6.51% | 4.29M | $28.14M |
| 3 | Braidwell LP | 4.72% | 3.11M | $20.37M |
| 4 | Frazier Life Sciences Management, L.P. | 3.99% | 2.63M | $17.26M |
| 5 | Vanguard Capital Management LLC | 3.75% | 2.47M | $16.21M |
| 6 | Soleus Capital Management, L.P. | 3.41% | 2.25M | $14.73M |
| 7 | Stonepine Capital Management, LLC | 2.67% | 1.76M | $11.54M |
| 8 | Millennium Management Llc | 2.22% | 1.46M | $9.59M |
| 9 | Armistice Capital, LLC | 2.12% | 1.40M | $9.16M |
| 10 | Geode Capital Management, LLC | 2.10% | 1.38M | $9.06M |
Analyst View
Loading analyst coverage…
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for EOLS
No recent headlines available.